Medmonitor

The Journal of the American Medical Association (JAMA) recently published a new investigation that explored if semaglutide and tirzepatide – GLP-1 drugs popular for the treatment of diabetes and obesity – reduce the risk of hospitalization for heart failure or all-cause mortality in patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes. The investigation utilized five cohort studies using national US health care claims data from 2018 to 2024. Patients initiating semaglutide or tirzepatide had a more than 40% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin (a glucose-lowering drug with no effect on heart failure end points). Tirzepatide showed no meaningful benefit over semaglutide. These findings complement early results from small clinical trials and support the use of semaglutide and tirzepatide in patients with cardiometabolic heart failure with preserved ejection fraction.

Golden State Medical Supply, Incorporated initiated a voluntary recall of Clopidogrel 75mg Tablets (lot# GS046745) and Atenolol 25mg Tablets (lot #GS046745) due to a label mix-up. Atenolol is indicated for the treatment of hypertension, to lower blood pressure, while Clopidogrel is prescribed to lower the risk of having a stroke, blood clot, or serious heart problem for patients who have had heart attack, severe chest pain, or circulation problems. Patients who suddenly stop taking atenolol are at increased risk for ischemic hypertensive and arrhythmic adverse events relating to rapid withdrawal of beta antagonism. Further, patients who are on atenolol are frequently on concomitant anticoagulant and antiplatelet medications and would be at increased risk for bleeding if clopidogrel were added to the regimen.

Aurobindo Pharma USA, Inc. has initiated a voluntary recall of two lots of Quinapril and Hydrochlorothiazide Tablets USP 20mg / 12.5mg – fixed combination tablets indicated to lower blood pressure and treat hypertension – due to presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Quinapril above the proposed interim limit. These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time. The lot numbers impacted are QE2021005-A and QE2021010-A. The tablets are pink colored, scored, round shaped, biconvex, film-coated tablets, debossed with “D” on the scored side and “19”on other side, supplied in 90’s HDPE bottle.